Piotr Halicki, MD

Department of Haematology, Medical University of Bialystok, Poland

Poster(s):

• 1406 - Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult Leukemia Group